Research To Practice

User Login | Create Account | Contact Us

  • Facebook
  • Instagram
  • X
  • LinkedIn
  • TikTok
  • Home
  • Browse By Tumor Type
  • Upcoming Events
  • About Us
  • Subscribe
  • CME Post-Tests
Home
We've determined that you are accessing this site using a mobile device. Please select which version of the site you would like to browse.

RTP On Demand: Current Controversies and Emerging Data Sets in Follicular Lymphoma and Chronic Lymphocytic Leukemia


  • Home
  • CME test
  • CME information and faculty disclosures
  • Select publications
Targeted therapies in lymphomas and CLL: BTK, Syk and PI3Kδ inhibitors
5:39 minutes.
NEXT VIDEO:
Case 1: 59-year-old woman with Stage IE, Grade 3A FL
Related videos:
  • BRIGHT and StiL NHL1-2003 studies of bendamustine/rituximab versus rituximab/chemotherapy in NHL
  • Rituximab schedule and maintenance in FL
  • Rituximab combined with lenalidomide (R squared) in untreated lymphoma
  • Type II anti-CD20 monoclonal antibody obinutuzumab in CLL
  • Novel agents in FL and CLL: BTK inhibitors
  • Case 1: 59-year-old woman with Stage IE, Grade 3A FL
  • Case 2: 48-year-old woman diagnosed 10 years ago with FL
  • Case 3: 62-year-old man with Grade 1 FL and Stage IIA colon adenocarcinoma
  • Case 4: 60-year-old man with asymptomatic progression of CLL
  • Subscribe to RTP Programs
  • Podcast
  • Download Mobile App
  • Privacy Policy
  • Terms of Use

Copyright © 2025 Research To Practice. All Rights Reserved.